Press Release Details

Jun 9, 2022

Concert Pharmaceuticals to Participate in Fireside Chat at The JMP Securities Life Sciences Conference

LEXINGTON, Mass.--(BUSINESS WIRE)--Jun. 9, 2022-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will participate in a fireside chat at The JMP Securities Life Sciences Conference on June 16, 2022 at 1:00 p.m. ET in New York, NY.

A webcast of the JMP fireside chat may be accessed in the Investors section of the Company’s website at A replay of the webcast will be available on Concert’s website for two weeks following the presentation.

About Concert

Concert Pharmaceuticals is a clinical stage biopharmaceutical company that is developing small molecule drugs that it discovered through the application of its DCE Platform® (deuterated chemical entity platform). Selective incorporation of deuterium into known molecules has the potential, on a case-by-case basis, to provide better pharmacokinetic or metabolic properties, thereby enhancing their clinical safety, tolerability or efficacy. Concert’s lead product candidate is in late-stage development for the treatment of alopecia areata, a serious autoimmune dermatological condition. Concert is also assessing a number of earlier-stage pipeline candidates. For more information please visit or follow us on Twitter at @ConcertPharma or on LinkedIn.

Justine Koenigsberg
(781) 674-5284

Source: Concert Pharmaceuticals, Inc.

Back to Top